Bone Metabolism After Laparoscopic Gastric Bypass Surgery (BABS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Bariatric surgery leads to rapid weight loss in female and male patients. Less data are available about its impact on bone metabolism.
The aim of this study is the investigation of changes in bone mineral density,bone histomorphometric changes, serum bone turnover markers and changes in body fat and muscle composition in patients after laparoscopic gastric bypass surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Evaluation of Expected Bone Loss After Bariatric Surgery Possible Prevention of Bone Loss After Surgery by Calcium and Vitamin D Supplementation |
Drug: Calciferol, calcium carbonate |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase 2 Study of Patients Undergoing Bariatric Surgery (Laparoscopic Gastric Bypass) and Evaluation of Bone Metabolism With/Without Vitamin D/Calcium Supplementation |
- Evaluation of bone mineral density changes in obese patients after laparoscopic bariatric surgery [ Time Frame: Evaluation every 6 months for 24 months ] [ Designated as safety issue: Yes ]
Dual energy X-ray absorptiometry (DXA) measurements of bone mineral density at lumbar spine, hip, calcaneus and total body will be performed at baseline and every six months for a period of 24 months.
Differences will be evaluated on the outcome with/without daily calcium (500mg) and weekly vitamin D (16.000 IU calciferol) supplementation
- Evaluation of changes of serum bone turnover markers in obese patients after laparoscopic bariatric surgery [ Time Frame: Evaluation every 3 months for 24 months ] [ Designated as safety issue: Yes ]
Fasting serum markers of bone formation and bone resorption will be evaluated:
Calcium, 25-OH-vitamin D3, intact parathyroid hormone, beta-crosslaps, type-1-procollagen, bone specific alkaline phosphatase, osteocalcin, sclerostin, osteoprotegerin, cathepsin-K, fibroblast factor 23, lipoprotein A, dickkopf 1 Differences will be evaluated on the outcome with/without daily calcium (500mg) and weekly vitamin D (16.000 IU calciferol) supplementation
- Evaluation of histomorphometric and histologic changes in obese patients after laparoscopic bariatric surgery [ Time Frame: baseline and after 24 months ] [ Designated as safety issue: Yes ]
Transiliac bone biopsies will be performed in a approximately 15% of patients at baseline and after 24 months.
The following parameters will be measured: bone volume (BV/TV), bone surface (BS/BV), osteoblast surface (OS/BS), trabecular number (TbN), trabecular thickness (TbTh, trabecular separation (Tb.sp), mineralized surface (MS/BS), mineral apposition rate (MAR) Differences will be evaluated on the outcome with/without daily calcium (500mg) and weekly vitamin D (16.000 IU colecalciferol) supplementation
| Estimated Enrollment: | 160 |
| Study Start Date: | November 2012 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | May 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Calcium/Vitamin D
All subjects will receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery as follows: daily: 500 mg oral calcium (calcium carbonate) weekly: 16.000 IU oral vitamin D3 (calciferol) |
Drug: Calciferol, calcium carbonate |
|
No Intervention: No Calcium/Vitamin D
All subjects will not receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery.
|
Detailed Description:
Obese female and male adult patients eligible for laparoscopic gastric bypass surgery according to the national Austrian guidelines will be included in this study upon request and after patient approval.
Baseline data collection and quarterly follow up visits are planned to investigate the changes in bone mineral density and body composition measured by dual energy X-ray absorptiometry as well as the evaluation of serum bone turnover markers of bone formation and resorption.
After surgery subjects will be randomized into two groups:
Daily oral calcium (500mg) and weekly vitamin D3 supplementation (16.000 IU calciferol)or no supplementation of calcium and calciferol.
A sub-study (approximately 15% of study population) with transiliac bone biopsies will also be performed to investigate histomorphometric and histologic changes in bone (biopsy baseline and after 24 months).
The planned duration of the study is 24 months for each subject. Serum bone turnover markers will be collected every 3 months, dual energy X-ray absorptiometry measurements will be performed every 6 months.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- body mass index >35
- female and male patients
- age 18 - 65 years
- eligible for laparoscopic gastric bypass surgery according to the Austrian national guidelines
Exclusion Criteria:
- any history of malignancy except basalioma
- any prior antiresorptive treatment
- any prior calcium or vitamin D supplementation
- any secondary disease affecting bone metabolism
Contacts and Locations| Austria | |
| Medical University Vienna | Recruiting |
| Vienna, Austria, 1060 | |
| Contact: Christian Muschitz, M.D. +43159988 ext 2119 christian.muschitz@bhs.at | |
| Contact: Heinrich Resch, M.D. +43159988 ext 2119 heinrich.resch@bhs.at | |
| Principal Investigator: Christian Muschitz, M.D. | |
| Sub-Investigator: Heinrich Resch, M.D. | |
| Sub-Investigator: Alexander Klaus, M.D. | |
| Sub-Investigator: Natascha Tykalsky, M.D. | |
| Principal Investigator: | Christian Muschitz, M.D. | Medical University Vienna - Austria |
More Information
Additional Information:
No publications provided
| Responsible Party: | Dr. Christian Muschitz, Senior Consultant for Internal Medicine, Medical University of Vienna |
| ClinicalTrials.gov Identifier: | NCT01739855 History of Changes |
| Other Study ID Numbers: | Vinforce-015, Vinforce 015 |
| Study First Received: | November 23, 2012 |
| Last Updated: | November 28, 2012 |
| Health Authority: | Austria: Institutional Review Board St.Vincent Hospital Vienna |
Additional relevant MeSH terms:
|
Calcium, Dietary Cholecalciferol Ergocalciferols Vitamin D Calcium Carbonate Vitamins Bone Density Conservation Agents |
Physiological Effects of Drugs Pharmacologic Actions Antacids Molecular Mechanisms of Pharmacological Action Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on June 18, 2013